Skip to main content
Top
Published in: BMC Geriatrics 1/2024

Open Access 01-12-2024 | Dementia | Correction

Correction to: Healthcare and community stakeholders’ perceptions of barriers and facilitators to implementing a behavioral activation intervention for people with dementia and depression: a qualitative study using Normalization Process Theory

Authors: Frida Svedin, Oscar Blomberg, Anders Brantnell, Paul Farrand, Anna Cristina Åberg, Joanne Woodford

Published in: BMC Geriatrics | Issue 1/2024

Login to get access

Excerpt

After publication of this article, the authors reported that in the abstract, in the first sentence of the paragraph ‘Results’, ’Twelve’ should have read ‘Ten’ …
Metadata
Title
Correction to: Healthcare and community stakeholders’ perceptions of barriers and facilitators to implementing a behavioral activation intervention for people with dementia and depression: a qualitative study using Normalization Process Theory
Authors
Frida Svedin
Oscar Blomberg
Anders Brantnell
Paul Farrand
Anna Cristina Åberg
Joanne Woodford
Publication date
01-12-2024
Publisher
BioMed Central
Keywords
Dementia
Dementia
Published in
BMC Geriatrics / Issue 1/2024
Electronic ISSN: 1471-2318
DOI
https://doi.org/10.1186/s12877-024-04829-1

Other articles of this Issue 1/2024

BMC Geriatrics 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine